Original Article

You have full text access to this OnlineOpen article

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

  1. Farhad Ravandi MD†,*,
  2. Jean-Pierre Issa MD,
  3. Guillermo Garcia-Manero MD,
  4. Susan O'Brien MD,
  5. Sherry Pierce BSN,
  6. Jianqin Shan PhD,
  7. Gautam Borthakur MD,
  8. Srdan Verstovsek MD,
  9. Stefan Faderl MD,
  10. Jorge Cortes MD,
  11. Hagop Kantarjian MD

Article first published online: 30 SEP 2009

DOI: 10.1002/cncr.24661

Issue

Cancer

Cancer

Volume 115, Issue 24, pages 5746–5751, 15 December 2009

Additional Information

How to Cite

Ravandi, F., Issa, J.-P., Garcia-Manero, G., O'Brien, S., Pierce, S., Shan, J., Borthakur, G., Verstovsek, S., Faderl, S., Cortes, J. and Kantarjian, H. (2009), Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer, 115: 5746–5751. doi: 10.1002/cncr.24661

Author Information

  1. Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 563-5774

*Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030

Publication History

  1. Issue published online: 2 DEC 2009
  2. Article first published online: 30 SEP 2009
  3. Manuscript Accepted: 12 MAR 2009
  4. Manuscript Revised: 5 MAR 2009
  5. Manuscript Received: 15 JAN 2009

Funded by

  • National Cancer Institute. Grant Number: 5P01 CA108631

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (154K)

References

  • 1
    Keating MJ, Cork A, Broach Y, et al. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res. 1987; 11: 119-133.
  • 2
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood. 1998; 92: 2322-2333.
  • 3
    Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001; 98: 1312-1320.
  • 4
    Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336.
  • 5
    Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 1997; 90: 2931-2938.
  • 6
    Estey E, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997; 90: 2969-2977.
  • 7
    Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20: 2429-2440.
  • 8
    Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 1794-1803.
    Direct Link:
  • 9
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10: 200-201.
  • 10
    Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006; 24: 3895-3903.
  • 11
    Estey EH, Pierce S, Keating MJ. Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica. 2000; 85: 246-249.
  • 12
    Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008; 112: 1638-1645.
  • 13
    Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006; 108: 45-51.
  • 14
    Rytting M, Verstovsek S, Garcia-Manero G, et al. Intensively timed induction (ITI) chemotherapy in adults with acute myelogenous leukemia (AML). Blood. 2007; 110. Abstract 1851.
  • 15
    Stone RM, Fischer T, Paquette R, et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61. Blood. 2006; 108. Abstract 157.
  • 16
    Kornblau SM, Banker DE, Stirewalt D, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood. 2007; 109: 2999-3006.
  • 17
    Delmonte J, Kantarjian HM, Garcia-Manero G, et al. Final update of phase I-II study of the farnesyltransferase inhibitor tipifarnib in combination with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2007; 110. Abstract 441.
  • 18
    Estey EH, Thall PF, Pierce S, et al. Randomized phase 2 study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999; 93: 2478-2484.
  • 19
    Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol. 2007; 25: 25-31.
  • 20
    Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007; 109: 52-57.
  • 21
    Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1 of 2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006; 108: 3271-3279.
  • 22
    Ravandi R, Faderl S, Thomas D, et al. Phase I study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis leukemia. Blood. 2007; 110. Abstract 897.
  • 23
    Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007; 110: 2302-2308.
View Full Article (HTML) Get PDF (154K)